Malwin Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.10 M
- Revenue Growth 115.54%
- Profit Growth -140.93%
- Ebitda -113.60%
- Net Worth -2.31%
- Total Assets -29.14%
About Malwin Pharma
Malwin Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 February 2004 and has a history of 20 years and 11 months. Its registered office is in Rajkot, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.20 M.
The company has closed loans amounting to ₹6.10 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Umang Gosalia and Pradeep Gosalia serve as directors at the Company.
Company Details
-
Location
Rajkot, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231GJ2004PTC043664
-
Company No.
043664
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Feb 2004
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Malwin Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umang Gosalia
|
Director | 01-Sep-2021 | Current |
|
Pradeep Gosalia
|
Director | 24-Feb-2004 | Current |
Financial Performance of Malwin Pharma.
Malwin Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 115.54% increase. The company also saw a substantial fall in profitability, with a 140.93% decrease in profit. The company's net worth dipped by a decrease of 2.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Malwin Pharma?
In 2018, Malwin Pharma had a promoter holding of 49.95% and a public holding of 50.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Parmax Pharma LimitedUmang Gosalia is a mutual person
Charges (Loans)
₹0
₹6.10 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.61 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2016 | Hdfc Bank Limited | ₹4.10 M | Satisfied |
| 25 Feb 2016 | Hdfc Bank Limited | ₹1.10 M | Satisfied |
| 27 Apr 2015 | Hdfc Bank Limited | ₹0.90 M | Satisfied |
How Many Employees Work at Malwin Pharma?
Unlock and access historical data on people associated with Malwin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Malwin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Malwin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
